KALA BIO
KALA
27 hedge funds and large institutions have $17.3M invested in KALA BIO in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 26 → 27 (+1)
11.58% less ownership
Funds ownership: 68% → 56.43% (-12%)
76% less capital inflows, than outflows
Capital inflows: $764K | Capital outflows: $3.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$404K |
| 2 |
Woodline Partners
San Francisco,
California
|
+$162K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.7K |
| 4 |
Renaissance Technologies
New York
|
+$67.9K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
+$50.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.41M |
| 2 |
Perceptive Advisors
New York
|
-$868K |
| 3 |
ADAR1 Capital Management
Austin,
Texas
|
-$582K |
| 4 |
Readystate Asset Management
Chicago,
Illinois
|
-$243K |
| 5 |
UBS O'Connor
Chicago,
Illinois
|
-$126K |
KALA Hedge Fund Activity: Q2 2025 in Review
27 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q2 2025, worth a combined $17.3M — down 27% from $23.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KALA positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $404K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $1.41M sold.
- 27 institutional investors held KALA BIO (KALA) as of Q2 2025, up from 26 in Q1 2025.
- Funds reported $17.3M of KALA BIO stock for Q2 2025, down 27% quarter-over-quarter.
- 4 funds opened new KALA BIO positions in Q2 2025 and 3 closed out, a net change of +1 holder.
- The largest KALA BIO buyer in Q2 2025 was AIGH Capital Management, an estimated $404K added.
- The largest KALA BIO seller in Q2 2025 was Silverarc Capital Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q2 2025.